ClinicalTrials.gg
RecruitingNCT07215988Updated Jun 25, 2026

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

An observational study in Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 and Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Ohio State University Comprehensive Cancer Center · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Planned enrollment
15th of 26
70 · median 80
Started
2026
with 9 others
Observational
27 of 171
2 open now
Primary completion
2027-12
later than 27 of 37 live
Registered
161st of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 15th largest by planned enrollment of the 26 observational ones that give a count, is one of 10 that started in 2026, is one of 27 observational ones, reaches primary completion later than 27 of the 37 other live ones, and was the 161st registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the time spent on obtaining insurance approval and drugs, means of insurance coverage, out-of-pocket costs for patients, and the surgical outcomes after neoadjuvant treatment is completed in skin cancer patients receiving "off label" and "on label" neoadjuvant treatment. "Neoadjuvant therapy" means cancer treatment given before surgery. However, in many instances, neoadjuvant therapy is used as an "off-label" approach for several types of skin cancers. "Off-label" means that the FDA has not yet approved its use for that type of cancer. Therefore, insurance approval of these "off-label" treatments could be delayed compared to label use, and "off-label" treatments may require several weeks of pre-authorization. There is evidence that the delayed start of cancer treatment can lead to poorer outcomes.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess in real-life clinical practice, the timing, cost, and surgical outcomes of patients who have resectable various skin cancers that are locally advanced or have a high risk of recurrence.

OUTLINE: This is an observational study.

Patients complete a survey and have their medical records reviewed on study.

03

Conditions studied

  • Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8
  • Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
  • Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
  • Locally Advanced Basal Cell Carcinoma
  • Locally Advanced Malignant Skin Neoplasm
  • Locally Advanced Merkel Cell Carcinoma
  • Locally Advanced Mucosal Melanoma
  • Locally Advanced Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with Merkel cell carcinoma, mucosal melanoma, basal cell carcinoma, and miscellaneous rare cutaneous cancers will be recruited from The James Comprehensive Cancer Center during the course of usual care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • * MERKEL CELL CARCINOMA

    • Signed
    • Pathology report confirming Merkel at the time of screening
    • Stage II, III or IV resectable (criteria based on Merkel Cell carcinoma TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with therapy
    • ≥ 18 years of age
    • Genomics of the cancer attempted
    • Description of planned surgical resection by surgeon
    • Planned treatment with immunotherapy. Possible Beacon plan entitled OP NIVOLUMAB IPILIMUMAB NEUROENDOCRINE (PRL 8149)

      • 2 cycles will be given prior to surgery (=12 weeks).

        • MUCOSAL MELANOMA
    • Signed informed consent
    • Pathology report confirming mucosal melanoma at the time of screening
    • Stage III or IV resectable (TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with neoadjuvant therapy
    • ≥ 18 years of age
    • Genomics of the cancer attempted
    • Description of planned surgical resection by surgeon
    • SOC (standard of care) treatment planned with immunotherapy Possible Beacon plan entitled OP NIVOLUMAB IPILIMUMAB -> NIVOLUMAB Q4 WEEK MAINTENANCE MELANOMA 4 cycles will be given prior to surgery (=12 weeks)

      • BASAL CELL CARCINOMA
    • Signed informed consent
    • Pathology report confirming basal cell carcinoma with subtype at the time of screening
    • Resectable tumor of any stage, or unresectable tumor that could be amenable to surgery if there is a good response.
    • ≥ 18 years of age
    • Genomics of the cancer attempted
    • Description of planned surgical resection by surgeon
    • SOC treatment planned with possible Beacon plan entitled OP SONIDEGIB BASAL CELL CARCINOMA 3 months will be given prior to surgery (= 12 weeks) (Vismodegib may be substituted if current national shortage of sonidegib persists)

      • RARE CUTANEOUS CANCERS
    • Signed informed consent
    • Pathology report confirming squamous cell carcinoma at the time of screening
    • Stage II, III, or IV resectable or (TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with neoadjuvant therapy
    • ≥ 18 years of age
    • Genomics of the cancer attempted
    • Description of planned surgical resection by surgeon
    • Planned SOC treatment with possible Beacon plan entitled OP WEEKLY CARBOPLATIN PACLITAXEL + PEMBROLIZUMAB Q3 WEEKS HEAD AND NECK

      • 4 cycles will be given prior to surgery (= 12 weeks)

Exclusion criteria

Exclusion Criteria:

  • * MERKEL CELL CARCINOMA

    • disease not amenable to complete resection
    • Prior immunotherapy, chemotherapy, or radiation therapy for treatment of MCC within the past year
    • Any medical condition, which in the judgment of the attending physician would contraindicate immunotherapy
    • Is pregnant or breast feeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.

      • MUCOSAL MELANOMA
    • Metastatic disease not amenable to complete resection
    • Prior immunotherapy, chemotherapy, or radiation therapy for treatment of this mucosal melanoma within the past year
    • Any clinically significant medical condition, which in the judgment of the attending physician would contraindicate immunotherapy
    • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.

      • BASAL CELL CARCINOMA
    • Metastatic disease not amenable to complete resection
    • Prior immunotherapy, chemotherapy, or radiation therapy for treatment of this basal cell carcinoma within the past year
    • Any clinically significant medical condition, which in the judgment of the attending physician would contraindicate immunotherapy
    • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.

      • RARE CUTANEOUS CANCERS
    • Metastatic disease not amenable to complete resection
    • Prior immunotherapy, chemotherapy, or radiation therapy for treatment of this mucosal melanoma within the past year
    • Any clinically significant medical condition, which in the judgment of the attending physician would contraindicate immunotherapy
    • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)

Groups and cohorts

  • Cohort 1: Merkel cell carcinoma

    Patients complete a survey and have their medical records reviewed on study.

    Other: Non-Interventional Study

  • Cohort 2: Mucosal melanoma

    Patients complete a survey and have their medical records reviewed on study.

    Other: Non-Interventional Study

  • Cohort 3: Basal cell carcinoma

    Patients complete a survey and have their medical records reviewed on study.

    Other: Non-Interventional Study

  • Cohort 4: Rare cutaneous cancers

    Patients complete a survey and have their medical records reviewed on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. Time spent obtaining approval and drugs

    Start and end times for obtaining approval for drugs will be based on date the initial request is submitted by the provider and the date the drugs are obtained. Confidence intervals will provide precision for estimating the mean time spent on obtaining approval and drugs and out-of-pocket expenses for patients.

    Time frame: Up to study completion, up to 17 weeks

  2. Means of coverage

    Descriptive statistics will summarize the conditions of off label coverage among patients, with mean, median, interquartile range, min, and max for continuous variables and frequencies / percentages for categorical variables.

    Time frame: Up to study completion, up to 17 weeks

  3. Out of pocket expenses for patients

    Descriptive statistics will summarize the conditions of off label coverage among patients, with mean, median, interquartile range, min, and max for continuous variables and frequencies / percentages for categorical variables.

    Time frame: Up to study completion, up to 17 weeks

  4. Extent of surgical resection

    Planned vs empirical extent of surgical resection will be calculated and compared within each cohort, with Clopper-Pearson exact binomial 95% confidence intervals for the percent of patients receiving lesser extent of surgery.

    Time frame: Up to study completion, up to 17 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 40 observational studies under Carcinoma, Basal Cell, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 75. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 14, 2025
StartActual
Feb 4, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07215988
Responsible party
Claire Verschraegen (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Oct 14, 2025
Start date
Feb 4, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Claire F Verschraegen, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion